Skip to content

Pennisetum Purpureum in Sarcopenia Patients

Effects of Pennisetum Purpureum Health Food Supplementation on Muscle Mass and Muscle Strength

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05911516
Enrollment
40
Registered
2023-06-22
Start date
2023-06-01
Completion date
2024-03-31
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Brief summary

The purpose of this study was to investigate the effects of Pennisetum purpureum health food supplementation on muscle mass and muscle strength.

Detailed description

All participants performed anthropometric measurements (body height, body weight, BMI, blood pressure, body composition, upper arm circumference, and lower thigh circumference), blood collection (hormones, liver function, and kidney function), exercise test (grip strength and 10-m walking test), as well as questionnaire survey before supplementation. Participants were assigned to either the experimental (n=20) or placebo (n=20) group according to their body composition, upper arm circumference, and lower thigh circumference. The definition of insufficient muscle mass was based on the Asian working group for sarcopenia (AWGS) that skeletal muscle mass in extremities by dual-energy X-ray absorptiometry less than 7.0 kg/m2 in men and less than 5.4 kg/m2 in women is a necessary condition, and one of the following criteria were met: (1) handgrip strength less than 28 kg in men and less than 18 kg in women and (2) 5-time chair stand test over than12 seconds. The anthropometric measurements (body height, body weight, BMI, blood pressure, body composition, upper arm circumference, and lower thigh circumference), blood collection (hormones, liver function, and kidney function), exercise test (grip strength and 10-m walking test), as well as questionnaire survey, were collected after 8 weeks and 12 weeks of supplementation.

Interventions

DIETARY_SUPPLEMENTPennisetum purpureum

300mg Participants received 900mg of Pennisetum purpureum orally daily for 12 weeks

DIETARY_SUPPLEMENTPlacebo

Placebo

Sponsors

Taipei Medical University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

A double-blind, matched-pair study design

Intervention model description

Participants were assigned to either the experimental (n=20) or placebo (n=20) group according to their body composition, upper arm circumference, and lower thigh circumference.

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. adult between 18-75 years old 2. skeletal muscle mass in extremities by dual-energy X-ray absorptiometry less than 7.0 kg/m2 in men and less than 5.4 kg/m2 in women 3. one of the following criteria were met: (1) handgrip strength less than 28 kg in men and less than 18 kg in women and (2) 5-time chair stand test over than 12 seconds

Exclusion criteria

1. The volunteers have history of cardiovascular, liver, kidney, and diabetes mellitus 2. acute sport injury 3. participated in any clinical trials or experimental research in the last 3 months before our experiment 4. taking supplement during the experimental period 5. did not maintain their regular eating habit or drink alcohol

Design outcomes

Primary

MeasureTime frame
Body heightBaseline (before supplementation)
Body weightBaseline (before supplementation)
BMI (body mass index)Baseline (before supplementation)
Systolic blood pressureBaseline (before supplementation)
Diastolic blood pressureBaseline (before supplementation)
ASM (Appendicular Skeletal Muscle Mass)12 weeks of supplementation
Upper Arm CircumferenceBaseline (before supplementation)
Thigh CircumferenceBaseline (before supplementation)
Grip StrengthBaseline (before supplementation)
10-Meter Walk TestBaseline (before supplementation)
Testosterone levelBaseline (before supplementation)
Cortisol levelBaseline (before supplementation)
Growth Hormone levelBaseline (before supplementation)
Insulin-like Growth Factor-1Baseline (before supplementation)
follistain levelBaseline (before supplementation)
myostain levelBaseline (before supplementation)

Countries

Taiwan

Contacts

Primary ContactMing Ta Yang, Doctorate
yangrugby@tmu.edu.tw886-2-27361661

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026